| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/13/2000 | WO2000040248A1 Method and composition for treatment of female sexual dysfunction |
| 07/13/2000 | WO2000040247A1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040237A1 Antiviral method using mek inhibitors |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040217A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000040089A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | WO2000040088A1 Amide derivatives for antiangiogenic and/or antitumorigenic use |
| 07/13/2000 | WO2000040087A1 Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors |
| 07/13/2000 | WO2000040086A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | WO2000025764A3 Compositions for the treatment and prevention of cardiovascular diseases |
| 07/13/2000 | WO2000024741A3 Dihydropyridine compounds and their use as potassium channel openers |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000023063A3 Methods for inhibiting diabetic complications |
| 07/13/2000 | WO2000021987A3 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 07/13/2000 | WO2000021927A3 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 07/13/2000 | WO2000021487A3 Formoterol polymorphs |
| 07/13/2000 | WO2000018801A3 Ncam binding compounds |
| 07/13/2000 | WO2000017366A3 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug |
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000015204A3 Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| 07/13/2000 | WO2000007545A9 Apoptosis proteins |
| 07/13/2000 | WO2000006597A9 Endogenous constitutively activated g protein-coupled orphan receptors |
| 07/13/2000 | WO1999058096A9 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 07/13/2000 | DE19900743A1 Neue komplexbildende Proteine New complexing proteins |
| 07/13/2000 | DE19900674A1 Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung Binding partners for 5-HT5 receptors in migraine treatment |
| 07/13/2000 | DE19900503A1 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen mit erhöhten extrazellulären FasL-Titern, Verfahren zur prophylaktischen Eignungs- bzw. Qualitätskontrolle derselben, Verfahren zur Herstellung von Arzneimitteln zur Behandlung obiger Krankheiten mit gesteigerter Wirksamkeit Use of a composition for the manufacture of a medicament for the treatment of diseases with increased extracellular FasL titers method for the prophylactic or suitability quality control thereof, a process for the preparation of medicaments for the treatment of the above diseases with enhanced efficacy |
| 07/13/2000 | CA2778317A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2360396A1 Characterization of a calcium channel family |
| 07/13/2000 | CA2358586A1 Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors |
| 07/13/2000 | CA2358578A1 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |
| 07/13/2000 | CA2358438A1 Antiviral method using mek inhibitors |
| 07/13/2000 | CA2358430A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 07/13/2000 | CA2358296A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | CA2358241A1 Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors |
| 07/13/2000 | CA2358212A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | CA2358014A1 Gene therapy to promote angiogenesis |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357874A1 Cyclic compound |
| 07/13/2000 | CA2357811A1 Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356969A1 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases |
| 07/13/2000 | CA2356966A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2356919A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2356053A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 07/13/2000 | CA2355967A1 Astrocytes, their preparation and uses thereof |
| 07/13/2000 | CA2355308A1 3,4-dihydro-2h-benzo¬1,4|oxazinyl-methyl¬3-(1h-indol-3-yl)-alkyl|-amines |
| 07/13/2000 | CA2354638A1 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | CA2353636A1 Quinolinecarboxamides as antiviral agents |
| 07/13/2000 | CA2353634A1 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| 07/13/2000 | CA2353592A1 Method and composition for treatment of female sexual dysfunction |
| 07/12/2000 | EP1018513A2 Quinolinecarboxylic acid derivatives |
| 07/12/2000 | EP1018512A1 Novel basic derivatives of benz(e)isoindol-1-ones and pyrrolo(3,4-c)quinolin-1-ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use |
| 07/12/2000 | EP1018511A1 Isochroman compounds and their production process |
| 07/12/2000 | EP1018506A1 Substituted alkyltetramine derivatives |
| 07/12/2000 | EP1018341A1 Antistress agents and functional foods |
| 07/12/2000 | EP1018338A1 Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2 |
| 07/12/2000 | EP1018008A2 Method of identification of leads or active compounds |
| 07/12/2000 | EP1017980A2 Methods of the identification of pharmaceutically active compounds |
| 07/12/2000 | EP1017826A2 Compositions and methods for identifying pkb kinase inhibitors |
| 07/12/2000 | EP1017823A2 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/12/2000 | EP1017810A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 07/12/2000 | EP1017800A1 Antisense oligonucleotides against thymidylate synthase |
| 07/12/2000 | EP1017697A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 07/12/2000 | EP1017694A2 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives |
| 07/12/2000 | EP1017693A1 Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them |
| 07/12/2000 | EP1017691A1 Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 07/12/2000 | EP1017682A1 Novel angiogenesis inhibitors |
| 07/12/2000 | EP1017681A1 Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates |
| 07/12/2000 | EP1017680A1 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same |
| 07/12/2000 | EP1017678A1 1,5-diphenylpyrazole derivatives |
| 07/12/2000 | EP1017664A1 C3a receptor ligands |
| 07/12/2000 | EP1017412A1 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 07/12/2000 | EP1017407A2 Useful properties of human lactoferrin and variants thereof |
| 07/12/2000 | EP1017405A1 Therapeutic hemoglobin composition having isotropically increased size |
| 07/12/2000 | EP1017402A1 Control of acidic gut syndrome |
| 07/12/2000 | EP1017394A1 Cyclin dependent kinase inhibiting purine derivatives |
| 07/12/2000 | EP1017387A1 Vitronectin receptor antagonist |
| 07/12/2000 | EP1017386A1 GRANULAR PREPARATIONS OF 5-(2-ETHYL- 2$i(H)-TETRAZOL- 5-YL)-1-METHYL-1, 2,3,6-TETRAHYDROPYRIDINE |
| 07/12/2000 | EP1017385A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 |
| 07/12/2000 | EP1017384A1 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| 07/12/2000 | EP1017383A1 Thrombin inhibitors |
| 07/12/2000 | EP1017379A1 Therapeutic compositions |
| 07/12/2000 | EP1017378A1 Amide derivatives for the treatment of diseases mediated by cytokines |
| 07/12/2000 | EP1017377A2 Use of 6, 7-substituted 2-aminotetralines for the treatment of cytokine mediated inflammatory conditions |
| 07/12/2000 | EP1017376A1 Method of treating heart failure |
| 07/12/2000 | EP1017353A2 Therapeutic process for inhibiting nf-kappa b |
| 07/12/2000 | EP1017275A1 Polyamine treatment of neurological disorders |
| 07/12/2000 | EP0918545B1 Tumour therapy |
| 07/12/2000 | EP0822932B1 Piperidine derivatives as diuretic |
| 07/12/2000 | EP0720600B1 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases |
| 07/12/2000 | EP0628041B1 Heterocyclic compounds and their preparation and use |
| 07/12/2000 | EP0413762B1 Peptide analogs and their use as haptens to elicit catalytic antibodies |
| 07/12/2000 | CN1259959A GnRh antagonists being modified in positions 5 and 6 |
| 07/12/2000 | CN1259958A Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| 07/12/2000 | CN1259954A 3-substituted pyrido [3',4' : 4,5] thieno [2,3D} pyrimidine derivatives, prodn. and use thereof |
| 07/12/2000 | CN1259951A Novel pharmaceutically useful compounds |
| 07/12/2000 | CN1259950A Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors |